在您下載用藥資訊前可以先閱讀「癌症用藥知識您不可不知」
癌症藥物(專業版)
所有分類
- ALK TKI
- Angiogenesis
- BcrABL TKI
- BRAF inhibitors
- BTK inhibitors TKI
- CDK inhibitors
- Conjugated antibody
- EGFR TKI
- FGFR inhibitors TKI
- Her2 inhibitors TKI
- KRAS inhibitors TKI
- MEK inhibitors TKI
- Monoclonal antibody
- mTOR inhibitors
- Multikinase inhibitors
- NTRK inhibitors TKI
- PARP inhibitors
- Phosphoinositide 3-kinase inhibitors
- Proteasome inhibitors
- Immune modulator
- BCL-2 inhibitor
- FLT3 inhibitors
- JAK inhibitors
- IL6 inhibitors
- Bispecific Antibody
- RET inhibitors TKI
- MET inhibitor
- AKT inhibitor
- IDH1 Inhibitors
- IDH2 inhibitor
Antibody Drug Conjugate
標靶治療誕生:在1975年，柯勒(Kohler)與麥爾斯坦(Milstein)將B細胞與
Bispecific antibody 概論
癌症標靶治療藥物 Bispecific antibodies (單株抗體發展史與臨床應用) Clinical pharmacist: Lihua Fang 2024/09/08大綱 • 標靶治療誕生 : 在1975年，柯勒(Kohler)與麥爾斯坦(Milstein)將B細胞與骨髓瘤細胞(
Bruton tyrosine kinase (BTK) inhibitors
BTK Inhibitors in CLL and Lymphomas: Overview and Current Indications IMBRUVICA® (Ibrutinib)億珂® 膠囊 CALQUENCE (Acalabrutinib )克瘤康膠囊 BRUKINSA® (Zanubru
CDK4/6 inhibitors 概論
CDK4/6 inhibitors : 愛乳適(IBRANCE)、擊癌利 (KISQALI)、捷癌寧 (VERZENIO) 和信治癌中心醫院 資深臨床藥師: 方麗華Outlines • History of CDK4/6 Inhibitors (cyclin-dependent kinases
CDK4/6 inhibitors 臨床決策比較
CDK4/6 inhibitors ( Palbociclib , Ribociclib, abemaciclb) 臨床適應症決策與副作用比較
Chemotherapy 2.0 & Antibody 2.0 (化療2.0與抗體2.0) 精準腫瘤醫學的新時代
Chemotherapy 2.0 & Antibody 2.0 (化療2.0與抗體2.0) 精準腫瘤醫學的新時代 臨床藥師: 方麗華大綱 •簡介 •定義“2.0”概念: 從傳統至標靶 • Antibody 1.0 • 1975: Köhler 和 Milstein 發展雜交瘤技術（Hybridoma
Current Treatment Paradigm for NSCLC
Current Treatment Paradigm for NSCLC (transmembrane Tyrosine kinase receptors EGFR, ALK, ROS, MET, RET, NTRK ) Clinical pharmacist : lihua Fang 20
HER2 inhibitors
HER2 INHIBITORS Lihua Outlines ◦ History of Her2 overexpression ◦ Role in Cancer treatment ( Type of cancer, Driven gene, role of treatment ) ◦ D